All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Nimbus Therapeutics will host its second in a series of virtual seminars highlighting the latest data from its HPK1 program. Nimbus’ scientific leadership will present new preclinical data on the anti-tumor immune activity of its small-molecule HPK1 inhibitors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Nimbus will present new data on in vitro pharmacology and mechanism of action of the HPK1 inhibitors, including effects on T cells, B cells, dendritic cells and antigen presentation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 14, 2020
Details:
The funds support the acceleration of Nimbus’ Phase 1 allosteric tyrosine kinase 2 inhibitor into Phase 2 early next year, its hematopoietic progenitor kinase 1 inhibitor into the clinic next year, as well as the advancement of its preclinical portfolio of new medicines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NMBS-1
Therapeutic Area: Oncology Product Name: NMBS-1
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The lead compound, NMBS-1, displays very high selectivity against T cell-specific kinases and kinases in the MAP4K family and promising activity in in vitro and in vivo models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
The seminar will feature presentations by the scientific leadership of Nimbus that will provide a brief overview of the company 's discovery pipeline and the data contained in the company's poster presentation at the AACR Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
Additional Drug Discovery Targets are, AMP-activated protein kinase, β2 subunit, CTP synthase 1, Cbl proto-oncogene B and Werner syndrome ATP-dependent helicase, for which Nimbus’ structure-based discovery approaches are uniquely suited.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Data to be presented at 2020 AACR Annual Meeting show HPK1 inhibition produced robust anti-tumor response in mouse model.